Neumora Therapeutics IPO Presentation Deck
Neumora is Poised to Become the Leader in Brain Health with Multiple
Catalysts Expected Through 2025 to Drive Value
Built at Scale
Raised >$600M to date from leading investors with a team of
expert company builders and neuroscience drug developers
2023
Navacaprant
Initiate KOASTAL-1 Study (3Q23)
Initiate KOASTAL-3 Study (4Q23)
Initiate KOASTAL-LT (2H23)
●
●
NMRA-266
●
IND submission (4Q23)
Leading Pipeline
Advancing seven programs with NCE therapeutic candidates with
novel MOAS in areas of significant unmet need
2024
Navacaprant
Initiate KOASTAL-2 Study (1Q24)
Topline data readout from
KOASTAL-1 study (2H24)
Initiate clinical study in bipolar
depression (1H24)
NMRA-511
Initiate study in agitation in
Alzheimer's disease (1H24)
Innovative Approach
Maximizing the value of our programs to potentially increase the
odds of clinical success and expand indications
2025
Navacaprant
Data readout from KOASTAL-2 and
KOASTAL-3 studies (1H25)
●
NDA submission in MDD
monotherapy (2025)
Confidential
28View entire presentation